Alexion Archives - Page 3 of 7 -

Janssen J&J Johnson and Johnson pharmaceutical companies

Johnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain

J&J’s Darzalex Faspro is first US therapy for rare blood disorder

https://pharmaphorum.com/news/jjs-darzalex-faspro-is-first-us-therapy-for-rare-blood-disorder/

News/ News/ Sales and Marketing

Alexion finally has a buyer – and it’s AstraZeneca with $39bn on the table

Phil Taylor Alexion, AstraZeneca, M&A 0 Comment

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and

Alexion finally has a buyer – and it’s AstraZeneca with $39bn on the table

https://pharmaphorum.com/news/alexion-finally-has-a-buyer-and-its-astrazeneca-with-39bn-on-the-table/

News/ News/ R&D

Chasing Janssen, Alexion and Caelum start phase 3 AL amyloidosis trial

Richard Staines AL amyloidosis, Alexion, Caelum Biosciences, Rare diseases 0 Comment

Alexion and development partner Caelum Biosciences have begun late-stage trials of their light-chain (AL) amyloidosis drug CAEL-101, snapping

Chasing Janssen, Alexion and Caelum start phase 3 AL amyloidosis trial

https://pharmaphorum.com/news/chasing-janssen-alexion-and-caelum-start-phase-3-al-amyloidosis-trial/

News/ News/ Sales and Marketing

Roche takes on Alexion as FDA approves satralizumab in NMOSD

Richard Staines Alexion, inflammatory diseases, neurology, NMOSD, Roche 0 Comment

The FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the

Roche takes on Alexion as FDA approves satralizumab in NMOSD

https://pharmaphorum.com/news/roche-takes-on-alexion-as-fda-approves-satralizumab-in-nmosd/

News/ News/ R&D

Alexion trials rare disease drug Ultomiris in severe COVID-19 cases

Richard Staines Alexion, coronavirus, COVID-19, Ultomiris 0 Comment

Pharma is pretty much throwing everything it has at COVID-19 and US rare disease firm Alexion has joined

Alexion trials rare disease drug Ultomiris in severe COVID-19 cases

https://pharmaphorum.com/news/alexion-trials-rare-disease-drug-ultomiris-in-severe-covid-19-cases/

News/ News/ R&D

Roche trumpets data for Soliris rival in NMOSD after US, EU filings

Phil Taylor Alexion, rare disease, Roche, satralizumab, Soliris 0 Comment

Roche has continued to build the case for satralizumab, its experimental therapy for rare disease neuromyelitis optica spectrum

Roche trumpets data for Soliris rival in NMOSD after US, EU filings

https://pharmaphorum.com/news/roche-trumpets-data-for-soliris-rival-in-nmosd-after-us-eu-filings/

News/ News/ Sales and Marketing/ Top stories

Alexion stalks rare disease drug from Stealth with $30m opt-in deal

Phil Taylor Alexion, licensing, rare disease, Stealth Therapeutics 0 Comment

Alexion has taken an option on a rare disease drug from Stealth Therapeutics in late-stage development, bolstering its

Alexion stalks rare disease drug from Stealth with $30m opt-in deal

https://pharmaphorum.com/news/alexion-stalks-rare-disease-drug-from-stealth-with-30m-opt-in-deal/

News/ News/ R&D/ Top stories

UCB sets sights on rare diseases giant Alexion with Ra Pharma acquisition

Richard Staines Alexion, Ra Pharma, Rare diseases, UCB 0 Comment

UCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage

UCB sets sights on rare diseases giant Alexion with Ra Pharma acquisition

https://pharmaphorum.com/news/ucb-takes-on-rare-diseases-giant-alexion-with-ra-pharma-acquisition/

News/ News/ R&D/ Top stories

Roche preps filings for satralizumab in rare disease NMOSD

Phil Taylor Alexion, rare disease, Roche, satralizumab, Soliris 0 Comment

Roche is two for two in its phase 3 trials programme for satralizumab in the rare disease neuromyelitis

Roche preps filings for satralizumab in rare disease NMOSD

https://pharmaphorum.com/news/roche-preps-filings-for-satralizumab-in-rare-disease-nmosd/

Trending

Alexion

Login